



Media Contact  
Dan McFadden  
[dmcfadden@oculusis.com](mailto:dmcfadden@oculusis.com)  
(425) 836-3103

## **OCULUS MICROCYN60™ DISINFECTANT (OMD™) TECHNOLOGY RECEIVES CE MARK APPROVAL AS DISINFECTANT FOR NON-CRITICAL MEDICAL DEVICES IN EUROPE**

**Oculus Microcyn60™ Disinfectant (OMD™) meets requirements of European Medical Device Directive and can be marketed in the European Market.**

**SITTARD, THE NETHERLANDS--(March 31, 2004)**— Oculus Innovative Sciences Netherlands B.V., a wholly owned subsidiary of Oculus Innovative Sciences of the United States, today announced that the company's first commercialized technology, the Oculus Microcyn60™ Disinfectant (OMD™), has received CE approval under the European Medical Devices Directive 93/42/EEC. The super-oxidized OMD solution has proven to be environmentally friendly while effectively eradicating bacteria.

The newly obtained CE Mark is based on compliance with the recently developed EN 13727 European test for bactericidal efficacy. Under the supervision of the Dutch notified body (TNO), OMD is one of the first disinfectants to meet these new, more rigorous standards in Europe.

"We are elated with this initial CE Mark for OMD," said Hoji Alimi, president and founder of Oculus Innovative Sciences, "And are continuing to work with the European regulatory agencies as we pursue further approvals as a high-level disinfectant and eventually as an antiseptic." The CE approval is also crucial to open other non-CE mark international markets such as Latin America, South Africa, Eastern Europe and the Middle East.

Microcyn™'s first regulatory approvals came from the Mexican Ministry of Health in July of 2003, allowing for the use of Microcyn in Mexico as a commercial disinfectant for hard surfaces and medical devices, as well as an antiseptic for use on patients for the irrigation of wounds and in pre-operative skin preparation. The Ministry subsequently approved Microcyn for use as a high-level sterilant in November 2003. As well, the company successfully filed its application for approval of the Microcyn technology as a disinfectant with the United States Environmental Protection Agency in March 2004.

In addition to disinfecting of medical devices, Microcyn has shown great promise in the areas of food sterilization, veterinarian market, consumer products, wound healing, oral surgery and uses related to anti-bioterrorism. The disruptive Microcyn technology has created a buzz within global disinfectant and antiseptic industries due to its uniquely non-flammable, environmentally friendly and effective nature in rapidly killing viruses, bacteria, mold and spores.

### **About Oculus**

Oculus Innovative Sciences, headquartered in Petaluma, California, is pioneering innovative technologies that globally re-define the disinfectant and antiseptic markets. Oculus has developed the revolutionary Microcyn disinfectant and antiseptic with broad applications in such diverse markets as consumer, medical, dental, veterinarian, cosmetic, wound healing, food processing and anti-bioterrorism. The company has employees and operations in Mexico, Europe and the U.S. and includes two wholly owned subsidiaries, Oculus Technologies of Mexico, S.A. de C.V., and Oculus Innovative Sciences Netherlands B.V. Please visit us at [www.oculusis.com](http://www.oculusis.com).

### **Forward-Looking Statements**

This press release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements relate to, among other things, plans and timing for the introduction of our products, statements about future market conditions, supply and demand conditions, revenues, gross margins, operating expenses, profits and other expectations, intentions and plans contained in this press release that are not historical fact. Our expectations as expressed in this press release depend upon our ability to develop, manufacture and supply products that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in the health sciences market. In light of the many risks and uncertainties surrounding this market, you should understand that we cannot assure you that the forward-looking statements contained in this press release will be realized.

### **Disclaimer**

This release concerns a use that has not been approved or cleared by the Food and Drug Administration or the Environmental Protection Agency.